Therapy

  • Rebuilding a life after brain injury: Mark’s story

    SweetTree Home Care Services reveal how adopting a structured, outcome-driven approach helped Mark rebuild his life after brain injury. Rebuilding a life after brain injury: Mark's story Imagine forgetting basic skills—how to brush your teeth, make a cup of tea, or even where you live. For Mark, a 49-year-old man living in London with temporal [...]

  • Patient story: How ‘brain pacemaker’ saved conductor’s career

    A music conductor in the US has returned to the podium after receiving innovative brain technology that controls his Parkinson's tremors, allowing him to lead his symphony with renewed confidence. Rand Laycock*, 70, was diagnosed with Parkinson’s disease shortly before turning 60 after seeking medical advice for thumb twitching. The retired music teacher has guided [...]

  • AI-powered speech therapy platform for neurological conditions helps to remove language barriers

    For the first time, Spanish and Indian English speakers recovering from stroke, traumatic brain injury (TBI), aphasia, apraxia, dementia, or other neurological conditions can access a comprehensive library of culturally and linguistically tailored cognitive rehabilitation exercises from their homes. Spanish is the most common non-English language spoken in the United States, with millions of speakers [...]

  • Can exercise and rehab services be integrated into breast cancer care?

    A new trial has revealed the potential of a programme designed to connect patients who have breast cancer to needed exercise and rehabilitation services starting at diagnosis and throughout care. Exercise services for individuals with breast cancer can improve functional deficits, fitness, and strength. Rehabilitation services treat neurological and musculoskeletal deficits, such as impaired shoulder [...]

  • Gene replacement therapy for spinal muscular atrophy shows positive trial results

    A Phase 3 trial of intrathecal onasemnogene abeparvovec (OAV101 IT) - an investigational gene replacement therapy - in children ages two to 18 years with spinal muscular atrophy (SMA) has shown positive results. OAV101 IT is designed to directly address the genetic root cause of the disease by replacing the nonworking SMN1 gene with a [...]

  • Parakeet study could inform development of new speech therapies

    A new study investigating how a parakeet’s brain helps it to mimic human words has established the bird as an important animal model for investigating speech motor control, and researchers say the findings could help develop therapeutic solutions for addressing a range of communication disorders. By recording for the first time the brain activity of [...]

  • Fourier Rehab announces GReAT 2025 summit

    Fourier Rehab is set to host GReAT 2025, a premier global summit bringing together experts, innovators, and thought leaders in rehabilitation technology. Taking place at the Fourier Shanghai Headquarters from April 23-24, 2025, this exclusive event will provide insights into the latest advancements in assistive technology and rehabilitation solutions. Since its inception in 2020, the [...]

  • The power of personal goals in the rehabilitation journey

    By Victoria Sudworth, Clinical Commissioning Support Manager at The Daley Care Centre In rehabilitation, the importance of setting personal goals cannot be overstated. These goals shape the trajectory of an individual's recovery and provide a crucial sense of direction.   Rather than a one-size-fits-all approach, rehabilitation is most effective when tailored to the [...]

  • NR Times rehab tech roundup

    We round up the latest innovations in rehab tech, from falls detection in care homes to deep brain stimulation for Parkinson's BrainSense adaptive deep brain stimulation tech personalises Parkinson's therapy For 30 years, people with Parkinson's disease have benefitted from deep brain stimulation (DBS), a technology that transmits electric signals to the brain to disrupt [...]

  • J&J expands neurological drug portfolio with $14.6bn Intra-Cellular Therapies acquisition

    Johnson & Johnson (J&J) has confirmed it has acquired neurological drug developer Intra-Cellular Therapies in a US$14.6bn deal. The deal will see J&J strengthen is neurological drug portfolio with Intra-Cellular's central nervous system disorder therapeutics for conditions such as Alzheimer's Disease, bipolar disorder and major depressive disorder. This includes CAPLYTA (lumateperone), which is an approved [...]